BofA/Merrill Lynch Downgrades ResMed (RMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Citi Upgrades ResMed (RMD) to Buy
August 2, 2017 6:43 AM EDTCiti upgraded ResMed (NYSE: RMD) from Neutral to Buy.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $77.48 yesterday.
... MoreResMed (RMD) Tops Q4 EPS by 2c, Beats on Revenues
August 1, 2017 4:14 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $0.77, $0.02 better than the analyst estimate of $0.75. Revenue for the quarter came in at $556.7 million versus the consensus estimate of $555.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More